Research
Goldman Sachs Initiates Corvus Pharmaceuticals at Buy With $40 Price Target
Corvus Pharmaceuticals (CRVS) has an average rating of buy and mean price target of $35.86, according to analysts polled by FactSet.
$CRVS
$CRVS
1 story mentioning CRVSUpdated 136d ago
Every FINWIRES story that references CRVS, newest first.
What are analysts saying about CRVS?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
